+1-888-308-5802      . .

iBio unveils the first FastGlycaneering Development Service™

Author : Saipriya Iyer | Published Date : 2019-12-12 

iBio unveils the first FastGlycaneering Development Service™

iBio, a renowned New York based biotechnology firm, reportedly launched FastGlycaneering Development Service™, that includes a range of new glycosylation technologies to power high-performance recombinant protein production.

Using iBio’s plant-based manufacturing platform, biosimilar producers and biopharmaceutical innovators would be able to leverage low cost oligomannose modification capabilities, afucosylation controls, and conventional glycosylation techniques to develop novel antibody therapeutics, biosimilars and high-quality biobetters.

Tom Isett, a member of Board of Directors, iBio, reportedly stated that combining the speed of iBio’s FastPharming Manufacturing System™ with the advanced glycan engineering technologies creates a more effective and efficient alternative of producing biopharmaceuticals in cell-based mammalian systems or CHO. Isett further added that Dr. Sylvain Marcel, VP of Protein Expression Sciences is likely to unlock iBio’s N. benthamiana expression system with these innovations.

Robert B. Kay, CEO and Chairman, iBio, reportedly stated that the company has taken another step with proven results in the manufacturing of growth factors, virus-like particles, biologics, fusion proteins and monoclonal antibodies. The company is thrilled to present new services of FastGlycaneering during the Antibody Engineering & Therapeutics meeting held in San Diego, CA, during a talk.

About iBio:

iBio, Inc., is a globally recognized full-service biologics manufacturing firm. iBio’s FastPharming System™ combines automated hydroponics, glycan engineering and vertical farming technologies that are capable of rapidly delivering high-quality vaccines, bioinks, monoclonal antibodies and proteins.

The team of iBio comprises of knowledgeable microbiologists, protein scientists, regulatory and manufacturing experts that use their expertise and value throughout the entire process. The team producing clinical and preclinical material also produces products for market launch, thereby contributing to the scale-up process platform created by iBio technology.

The FastPharming platform produces a variety of products including, antigens for subunit vaccine design, VLP (Virus-like particles), lysosomal enzymes, biobetter and biosimilar antibodies, blood factors and cytokines, maturogens, scaffolds and, materials for 3D biofabrication and bioprinting.

 

Source credit: https://www.ibioinc.com/news/ibio-introduces-fastglycaneering-development-service-to-power-recombinant-protein-production

About Author

Saipriya Iyer . .

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Hero MotoCorp under investigation by Ministry of Corporate Affairs

Hero MotoCorp under investigation by Ministry of Corporate Affairs

Published Date: 2023-06-16         Author: Saipriya Iyer

The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>

UK: Residents receive bills of up to £49,000 after Ovo acquires SSE

UK: Residents receive bills of up to £49,000 after Ovo acquires SSE

Published Date: 2022-11-24         Author: Saipriya Iyer

Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>

Bob Iger returns to Disney as CEO less than a year post retirement

Bob Iger returns to Disney as CEO less than a year post retirement

Published Date: 2022-11-21         Author: Saipriya Iyer

Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>

© 2024 Fractovia. All Rights Reserved